✦ LIBER ✦

Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma

✍ Scribed by Gordon, Leo I.; Witzig, Thomas; Molina, Arturo; Czuczman, Myron; Emmanouilides, Christos; Joyce, Robin; Vo, Katie; Theuer, Charles; Pohlman, Brad; Bartlett, Nancy; Wiseman, Greg; Darif, Mohamed; White, Christine

Book ID: 119935798
Publisher: CIG Media Group, LP.
Year: 2004
Tongue: English
Weight: 128 KB
Volume: 5
Category: Article
ISSN: 1526-9655
DOI: 10.3816/clm.2004.n.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Use of Ibritumomab Tiuxetan Anti-CD20 Ra

Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90–Labeled Anti-CD22 Monoclonal Antibody

✍ Tsai, Donald E.; Maillard, Ivan; Schuster, Stephen J.; Nasta, Sunita D.; Porter, 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 478 KB

Treatment with yttrium 90 ibritumomab ti

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

✍ Emmanouilides, Christos; Witzig, Thomas E.; Gordon, Leo I.; Vo, Katie; Wiseman, 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 352 KB

Combining Yttrium 90–Labeled Ibritumomab

Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma

✍ Winter, Jane N. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 246 KB

The city of hope experience with novel t

The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

✍ A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 56 KB